ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct GLORA-4 study (NCT06641414), a global registrational Phase III study of lisaftoclax (APG-2575), a proprietary Bcl-2 inhibitor, in combination with azacitidine (AZA), for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).
Multicenter Registry Launches to Assess Real-World Outcomes and Clinical Integration of Nonthermal Aliya PEF Ablation
REDWOOD CITY, Calif., Aug. 15, 2025 /PRNewswire/ -- Galvanize Therapeutics...
The stem cell banking market is booming due to advancements in tech and regenerative medicine, rising healthcare spend, private investments, and ethical shifts favoring adult stem cells. Key opportunities lie in personalized healthcare, clinical trials, and expanding access globally, with North America leading market growth.
The stem cell banking market is booming due to advancements in tech and regenerative medicine, rising healthcare spend, private investments, and ethical shifts favoring adult stem cells. Key opportunities lie in personalized healthcare, clinical trials, and expanding access globally, with North America leading market growth.
Summer Appreciation Sales Offers 12% Off All Products
NEW YORK, Aug. 15, 2025 /PRNewswire/ -- BestQool , a pioneer manufacturer of home-use red light therapy...
First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile
SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight into its planned Phase 1 clinical trial of HemaXellerate, the company’s innovative stem cell-derived therapy, which has already received U.S. FDA clearance. While the initial focus is on treating aplastic anemia, a rare orphan indication, Regen BioPharma is evaluating expanded applications for this groundbreaking therapy in markets poised for significant growth.
PAPZIMEOS approval marks a historic milestone for the RRP patient community as the first and only FDA-approved therapy for the treatment of adults with...
The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...
The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...
TORRANCE, Calif., Aug. 14, 2025 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell...
Changes recommended in clinical trial design to include the voice of more people living with type 1 diabetes in evaluating therapy benefits
NEW YORK, Aug....
MarketNewsUpdates News Commentary
NEW YORK, Aug. 14, 2025 /PRNewswire/ -- The global drone market is poised to become one of the most important and fastest-growing...